What happened
Insilico Medicine announced that its board chairman, executive director, CEO and chief commercial officer Aleksandrs Zavoronkovs intends to buy additional shares in the company on the open market using personal funds.
The planned purchases are expected to take place within September 2026, with an estimated total of up to HK$16 million, while adhering to the Hong Kong Listing Rules and applicable regulations.
The move is driven by his confidence in the company's future development prospects and his recognition of its long-term investment value, after he previously invested in the company's D-round financing in 2022.
Why it matters
The chairman's plan to increase his stake signals insider confidence in the company's outlook, which may reassure investors about its direction.
This action follows his earlier financial backing during the D round, reinforcing his personal commitment to the firm's growth and potential.
Key facts
Aleksandrs Zavoronkovs serves as board chairman, executive director, CEO and chief commercial officer of Insilico Medicine.
The share purchase plan is scheduled to occur within September 2026, with an estimated maximum total of HK$16 million.
Zavoronkovs previously invested in the company's D-round financing in 2022.
What to watch next
Whether the planned open-market purchases are fully executed as stated, and any related regulatory disclosures or updates that may follow.
How the market responds to this demonstration of insider confidence once the buying activity takes place.